Diroximel Fumarate Q&A - clinical considerations.PNG (115.72 kB)
Download file

Diroximel Fumarate in Relapsing Forms of Multiple Sclerosis: A Profile of Its Use

Download (115.72 kB)
online resource
posted on 31.05.2021, 23:47 by Julia Paik

Declarations


Funding The preparation of this review was not supported by any external funding.


Authorship and Conflict of interest Julia Paik is a salaried employee of Adis International Ltd/Springer Nature, and declares no relevant conflicts of interest. All authors contributed to the review and are responsible for the article content.


Ethics approval, Consent to participate, Consent to publish, Availability of data and material, Code availability Not applicable


Additional information about this Adis Drug Review can be found here


Abstract


Diroximel fumarate (Vumerity®), an orally administered disease-modifying drug (DMD), expands the available treatment options for adults with relapsing forms of multiple sclerosis (MS), including clinically isolated syndrome, relapsing-remitting MS (RRMS), and active secondary progressive MS. It demonstrates bioequivalence to dimethyl fumarate and was developed to provide similar clinical benefits, but with an improved gastrointestinal (GI) tolerability profile. In RRMS patients who are treatment-naïve or were previously treated with interferon-β or glatiramer acetate, diroximel fumarate reduces annualized relapse rates, with most patients experiencing no relapses during treatment, and reduces the formation of new MS-associated brain lesions. Diroximel fumarate has an acceptable tolerability profile that is consistent with that of dimethyl fumarate, albeit with a significantly lower rate of GI adverse events.


© Springer Nature Switzerland AG 2021

History